In summary, our study offers a comprehensive analysis of the cellular composition of human ESCC, the impact of neoadjuvant anti-PD1 combination therapy on the immune landscape, and specifically highlights the phenotypic and functional heterogeneity of CAFs within the TME of ESCC. Here, PDCD1 is linked to esophageal squamous cell carcinoma.